Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluciclovine→

Fluciclovine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
222727-43-7
Molecular formula
C5H8FNO2
Molecular weight
133.12 g/mol
Drug class
18F-labelled synthetic amino acid PET radiotracerdiagnostic imaging agent
Mechanism of action
Transported into tumour cells primarily through amino acid transporters such as ASCT2 and LAT1. Increased uptake can identify recurrent prostate cancer tissue after treatment; it is not a therapeutic amino acid analogue.
Indications / reported uses
  • PET imaging to detect suspected recurrent prostate cancer in adults with rising prostate-specific antigen (PSA) after prior treatment; imaging findings should be interpreted with clinical and other diagnostic data

Sources: US DailyMed — AXUMIN (fluciclovine F18) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluciclovine Environmental Risk Assessment (ERA) (the Fluciclovine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.